Featured Research

from universities, journals, and other organizations

Despite Ongoing Safety Concerns, Study Finds Adverse Reactions From Contrast Agents Rarely Occur

Date:
September 21, 2009
Source:
American Roentgen Ray Society
Summary:
Iodinated and Gadolinium based contrast agents, frequently used during computed tomography and MRI scans to aid in the imaging process, are associated with a very low rate of adverse effects, according to a large cohort study.

Iodinated and Gadolinium based contrast agents, frequently used during computed tomography (CT) and MRI scans to aid in the imaging process, are associated with a very low rate of adverse effects, according to a large cohort study published in the October issue of the American Journal of Roentgenology (AJR).

The study, performed at the Mayo Clinic in Rochester, MN, included a total of 456,930 contrast doses administered. "Only 522 cases of adverse effects were identified," said Christopher H. Hung, MD, lead author of the study. "The overwhelming majority of adverse effects were mild, represented with nausea and vomiting and mild rash. Only 16 cases necessitated transfer for further observation and treatment," he said.

"Contrast agents are very safe to use and they are often essential in aiding the diagnosis of CT and MR studies. As our study suggests, with the advent of newer contrast agents we have been able to improve their power-ability and safety profile," said Dr. Hunt.

"While contrast reactions can occur, it is important to note that they are rarely severe. Most of the reactions we saw in our study were mild and did not require treatment other than observation and supportive care," he said.


Story Source:

The above story is based on materials provided by American Roentgen Ray Society. Note: Materials may be edited for content and length.


Cite This Page:

American Roentgen Ray Society. "Despite Ongoing Safety Concerns, Study Finds Adverse Reactions From Contrast Agents Rarely Occur." ScienceDaily. ScienceDaily, 21 September 2009. <www.sciencedaily.com/releases/2009/09/090921075505.htm>.
American Roentgen Ray Society. (2009, September 21). Despite Ongoing Safety Concerns, Study Finds Adverse Reactions From Contrast Agents Rarely Occur. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/09/090921075505.htm
American Roentgen Ray Society. "Despite Ongoing Safety Concerns, Study Finds Adverse Reactions From Contrast Agents Rarely Occur." ScienceDaily. www.sciencedaily.com/releases/2009/09/090921075505.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins